NewcelX Business Summary

NewcelX Ltd. (NCEL) is a clinical-stage biopharmaceutical company formed through the late-2025 merger of NLS Pharmaceutics and Kadimastem, operating as a dual-hub entity in Zurich, Switzerland, and Ness Ziona, Israel. The company’s business model focuses on the development and future licensing of transformative therapies, leveraging an integrated platform that combines human pluripotent stem cell (hPSC) technology with small-molecule neuroscience expertise. Its primary business segments are divided into regenerative cell therapies, headlined by the IsletRx program for Type 1 Diabetes, and neurodegenerative treatments, featuring the AstroRx cell therapy for Amyotrophic Lateral Sclerosis (ALS). NewcelX competes with specialized biotech firms such as Vericel Corporation, Neurosense Therapeutics, Silexion Therapeutics, and Chemomab Therapeutics, distinguishing itself through its "off-the-shelf" allogeneic cell manufacturing capabilities and a dual-track pipeline addressing both metabolic and central nervous system disorders. The company is led by Executive Chairman and CEO Ronen Twito, a veteran of pharmaceutical corporate development who previously spearheaded NLS Pharmaceutics' growth and public listing. Scientific operations are directed by Chief Scientific Officer Prof. Michel Revel, a pioneer in the biotech industry known for developing the blockbuster drug Rebif and founding Kadimastem. The leadership is further bolstered by a Scientific Advisory Board that includes neuroimmunology expert Prof. Tamir Ben-Hur and Dr. Julien Boisdron, a former Swiss big pharma executive appointed in January 2026 to oversee diabetes innovation. Publicly traded on the NASDAQ, NewcelX is supported by institutional investors and strategic equity facilities, including a $25 million equity line of credit intended to fund its upcoming U.S. Phase 2a clinical trials for ALS.